TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04023253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirabegron
Description: Mirabegron 25 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin
Description: Solifenacin 5 mg
Study: NCT00849329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib
Description: 1250mg lapatinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib plus esomeprazole
Description: 1250mg lapatinib plus esomeprazole 40mg
Study: NCT06195228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib plus anti-PD-1 antibody
Description: Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib plus anti-PD-1 antibody
Description: Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation
Study: NCT04404556

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Journey
Description: Web-based telehealth intervention focused on adherence barriers and problem-solving

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Standard of Care
Description: General education via the T1DToolkit website, as well as 4 phone calls with certified diabetes educators (CDEs) will be provided.
Study: NCT01402700

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visi-Pro™ Balloon Expandable Stent System
Description: Implantation of one or more study devices in the common and/or external iliac artery.
Study: NCT01467804

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sertraline plus placebo of JWXYJN
Description: oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JWXYJN plus placebo of Sertraline
Description: JWXYJN 3.6g/d plus placebo of sertraline
Study: NCT06021379

Intervention type: DRUG
Intervention: Trastuzumab
Description: AryoTrust (AryoGen Pharmed Trastuzumab) is given at a dosing of 6 mg/m2 after adjuvant chemotherapy completion every 3 weeks for 9 cycles.
Study: NCT01718067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VAKÜM system
Description: 15 minutes, twice a day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional manual ELTGOL technique
Description: 20 minutes twice a day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional manual ELTGOL technique
Description: 20 minutes twice a day
Study: NCT01761344

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative cortisol measurement.
Description: Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
Study: NCT03084484

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kiwifruit addition to the diet
Description: Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non Surgical periodontal treatment
Description: Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Surgical periodontal treatment
Description: Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
Study: NCT03491917

Intervention type: DEVICE
Intervention: DBT plus S-View
Description: DBT plus S-View images

Intervention type: DEVICE
Intervention: FFDM alone
Description: FFDM alone images
Study: NCT05331924

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IPL therapy
Description: Intense pulsed light therapy (IPL) is a non-coherent large wavelength high-intensity light in the range of 500-1200nm. It has been used by many investigators for the treatment of evaporative dry eye safely and effectively.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Punctal plugs
Description: Silicone punctal plugs are small pieces of silicone designed to block tear drainage through occluding the lacrimal punctum.
Study: NCT05331898

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: the education given increased the rational drug use of the parents.
Study: NCT04777903

Intervention type: OTHER
Intervention: collect date about all participants
Description: a standardized and structured questionnaire that included information on age, residence, education, pregnancy history, disease history, height, and conception method, after obtaining the consent of all participants.

Intervention type: OTHER
Intervention: collect date about all participants
Description: a standardized and structured questionnaire that included information on age, residence, education, pregnancy history, disease history, height, and conception method, after obtaining the consent of all participants.

Intervention type: OTHER
Intervention: collect date about all participants
Description: a standardized and structured questionnaire that included information on age, residence, education, pregnancy history, disease history, height, and conception method, after obtaining the consent of all participants.
Study: NCT02918799

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mpowerment
Description: MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
Study: NCT01618877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
Study: NCT02084342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tranexamic acid and sodium chloride injection
Description: 10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tranexamic acid and sodium chloride injection
Description: 10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 100ml, IV for 30min,before incision.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: desmopressin acetate injection
Description: 0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
Study: NCT02635425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 7 eggs collection
Description: vaginal US

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full eggs collection
Description: vaginal US
Study: NCT04236141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polatuzumab Vedotin
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 1.8mg/kg Polatuzumab Vedotin (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 90 mg/m2 Bendamustine (IV infusion) on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 90 mg/m2 Bendamustine (IV infusion) on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of 375 mg/m2 Rituximab (IV infusion) on Day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Participants will receive a total of 6 cycles (a cycle being 21 days) of Placebo (IV infusion) on Day 2 of Cycle 1 and Day 1 of Cycles 2-6.
Study: NCT03640559

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroguard

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT03865316

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SedLine Vs Comparator Test Group
Description: Subjects will receive electrodes that compare EEG signals between Masimo's SedLine system and the comparator's system.
Study: NCT06195228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib plus anti-PD-1 antibody
Description: Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib plus anti-PD-1 antibody
Description: Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenvatinib plus anti-PD-1 antibody
Description: Advanced thyroid cancer patients who don't harbor the above gene mutation or could not afford the cost of precision treatment even with the above gene mutation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Targets: precise treatment based on the target
Description: Advanced thyroid cancer patients who had other treatment targets not included above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Targets: precise treatment based on the target
Description: Advanced thyroid cancer patients who had other treatment targets not included above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Targets: precise treatment based on the target
Description: Advanced thyroid cancer patients who had other treatment targets not included above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Targets: precise treatment based on the target
Description: Advanced thyroid cancer patients who had other treatment targets not included above

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Other Targets: precise treatment based on the target
Description: Advanced thyroid cancer patients who had other treatment targets not included above
Study: NCT05397314

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Punalpin

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00401440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
Study: NCT03668756

Intervention type: PROCEDURE
Intervention: Computer-Assisted Navigation TKA
Description: TKAs were performed using the image-free CAS navigation system VectorVision
Study: NCT01770340

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Radical prostatectomy with implantation of allograft
Description: Interposition of resected neurovascular bundles with allograft Avance®

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Radical prostatectomy without implantation of allograft
Description: No interposition of resected neurvascular bundles
Study: NCT00712101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abciximab intracoronary
Description: administer abciximab bolus intracoronary during primary percutaneous coronary intervention

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abciximab intravenously
Description: administer abciximab bolus intravenously during primary percutaneous coronary intervention
Study: NCT00216034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tegafur-gimeracil-oteracil potassium (TS-1)
Description: From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur-gimeracil-oteracil potassium (TS-1)
Description: From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Krestin (PSK)
Description: From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
Study: NCT02509208

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SurgiClot haemostatic dressing
Description: haemostatic dressing
Study: NCT00109421

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project ÒRÉ
Description: Community-based adolescent social network HIV/STI intervention tailored to African American culture
Study: NCT03270748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GvHD prophylaxis
Description: Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
Study: NCT04042480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-CD228A
Description: SGN-CD228A administered into the vein (IV; intravenously)
Study: NCT03295305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Action-Based Cognitive Remediation

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unstructured support group
Study: NCT02380131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin plus Capecitabine
Description: A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herceptin
Description: Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
Study: NCT00157300

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin beta
Description: intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
Study: NCT03639740

Intervention type: DRUG
Group type: OTHER
Intervention: Secukinumab 150 milligram [Cosentyx]
Description: For intervention description: see arm/group description
Study: NCT05072405

Intervention type: DRUG
Group type: OTHER
Intervention: Simvastatin 20 mg (Zocor®, MSD)
Description: Simvastatin 20 mg given once alone, once with green tea extract and once with soy isoflavones extract.

Intervention type: DRUG
Group type: OTHER
Intervention: rosuvastatin 10 mg (Crestor®, Astra Zeneca)
Description: rosuvastatin 10 mg are given once alone, once with green tea extract and once with soy isoflavones extract.
Study: NCT04259502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhomboid intercostal block
Description: The block is regional anesthesia injection techniques performed under ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Erector spinae plane block
Description: The block is regional anesthesia injection techniques performed under ultrasound guidance.
Study: NCT02485717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinosad topical suspension, 0.9%
Description: Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
Study: NCT00790517

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Premier Lifestyle Intervention with DASH Diet
Description: Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
Study: NCT02497703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Knee robot
Study: NCT01941225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled iloprost 5.0 mcg
Description: Single administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single administration
Study: NCT01117376

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erythromycin
Description: Erythromycin 250 mg intravenous Q6h for 4 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylnaltrexone
Description: Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
Study: NCT00613626

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etoposide
Description: Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo oral daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZD6474
Description: ZD6474 100mg oral daily to be continued for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD6474
Description: ZD6474 100mg oral daily to be continued for the duration of the study.
Study: NCT01031836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.~Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545
Description: Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-545 600
Description: Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.~Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses.
Study: NCT04084561

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRHA
Description: participants will be asked to consider a hypothetical scenario in which genetic test results reveal that: 1) they carry genotypes that place African American smokers at a particularly high (\~50%-80%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly high concordance with African heritage (\~90%).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LRLA
Description: participants will be asked to consider a scenario in which genetic test results reveal that: 1) they are at normal (\~7%-10%) risk for the development of lung cancer, and 2) their genetic profile reflects a particularly low concordance with African heritage (\~10%).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRLA
Description: participants will receive High Risk, Low Ancestry (HRLA) hypothetical

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LRHA
Description: participants will receive Low Risk, High Ancestry (HRLA) hypothetical
Study: NCT02055365

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hepatitis B Vaccine (Recombinant)
Description: All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).